Ensysce Biosciences (ENSC) Share-based Compensation (2020 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Share-based Compensation of $66278.0 for Q3 2025, up 948.37% year-over-year from $6322.0 in Q3 2024, and down 25.98% quarter-over-quarter from $89539.0 in Q2 2025.
Ensysce Biosciences (ENSC) Share-based Compensation (2020 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Share-based Compensation for 6 consecutive years, with $66278.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Share-based Compensation rose 948.37% year-over-year to $66278.0; the TTM figure through Sep 2025 stood at $119000.0 (down 82.88% YoY), while the FY2024 annual figure was $110723.0, down 87.41% from the prior year.
- Share-based Compensation declined to $66278.0 in Q3 2025 per ENSC's latest filing, from $89539.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $1.7 million in Q1 2022 and bottomed at $3.0 in Q4 2022.
- Historically, Share-based Compensation has averaged $177006.8 across 5 years, with a median of $34790.0 in 2021.
- Annual changes were most pronounced in 2022 — Share-based Compensation slumped 99.98% — and 2023, when it soared 20964433.33%.
- Ensysce Biosciences' Share-based Compensation stood at $16738.0 in 2021, then plunged by 99.98% to $3.0 in 2022, then jumped by 20964433.33% to $628936.0 in 2023, then sank by 95.21% to $30149.0 in 2024, then soared by 119.83% to $66278.0 in 2025.
- Business Quant data shows ENSC's Share-based Compensation at $66278.0 in Q3 2025, $89539.0 in Q2 2025, and $16251.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 66,278.00 |
| Sep 30, 2025 | 66,278.00 |
| Jun 30, 2025 | 89,539.00 |
| Jun 30, 2025 | 89,539.00 |
| Mar 31, 2025 | 16,251.00 |
| Mar 31, 2025 | 16,251.00 |
| Dec 31, 2024 | 30,149.00 |
| Dec 31, 2024 | 30,149.00 |
| Sep 30, 2024 | 6,322.00 |
| Sep 30, 2024 | 6,322.00 |
| Jun 30, 2024 | 26,549.00 |
| Jun 30, 2024 | 26,549.00 |
| Mar 31, 2024 | 33,207.00 |
| Mar 31, 2024 | 33,207.00 |
| Dec 31, 2023 | 628,936.00 |
| Dec 31, 2023 | 628,936.00 |
| Sep 30, 2023 | 14,338.00 |
| Sep 30, 2023 | 14,338.00 |
| Jun 30, 2023 | 60,394.00 |
| Jun 30, 2023 | 60,394.00 |